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A B S T R A C T
In this paper, we describe the preparation of liver-targeted polymeric micelles potentially able to carry
sorafenib to hepatocytes for treatment of hepatocarcinoma (HCC), exploiting the presence of
carbohydrate receptors, ASGPR. These micelles were prepared starting from a galactosylated
polylactide-polyaminoacid conjugate. This latter was obtained by chemical reaction of a,b-poly(N-2-
hydroxyethyl) (2-aminoethylcarbamate)-D,L-aspartamide (PHEA-EDA) with polylactic acid (PLA), and
subsequent reaction with lactose, leading to PHEA-EDA-PLA-GAL copolymer. Liver-targeted sorafenib-
loaded micelles were obtained in aqueous media at low PHEA-EDA-PLA-GAL copolymer concentration
value with nanometer size and slightly positive zeta potential. Biodistribution studies on mice
demonstrated, after oral administration of sorafenib loaded PHEA-EDA-PLA-GAL micelles, the
preferential sorafenib accumulation into the liver. This ﬁnding raises hope in terms of future drug
delivery strategy of sorafenib-loaded micelles targeted to the liver for the HCC treatment.
ã 2014 Elsevier B.V. All rights reserved.
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Liver diseases are the major causes of disability and mortality
worldwide (Li et al., 2010). In the absence of a satisfactory curative
option, the pursuit of alternative pharmacological interventions,
therefore, remains extremely pressing. Many potent drugs are often
not effective enough in vivo or exhibit adverse effects. Although they
accumulate rapidly in the liver, they do not accumulate in the proper
intrahepatic cell-type; thus drug targeting to the liver may represent
a new promising strategy (Poelska et al., 2012). For several diseases,
hepatocytes represent the most relevant target cell, playing a crucial
role in viral hepatitis, steatohepatitis, some genetic diseases and
several other metabolic disorders. However, the major issue is not
drug uptake by hepatocytes; but other competing processes such as
the ﬁrst pass effect or drug uptake by other cell-types may occur.
Many efforts have been dedicated to the targeted delivery of drugs
and genes in particular to hepatocytes by the development of* Corresponding author at: Lab of Biocompatible Polymers, Dipartimento di
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0378-5173/ã 2014 Elsevier B.V. All rights reserved.galactosylated polymeric or lipid carriers in order to enhance the
therapeutic effects (in case of hepatocellular carcinoma, viral
hepatitis or gene-based therapies) or to reduce side-effects of drugs
(in case of antiviral or anticancer drugs) (Poelska et al., 2012).
Galactosylationisaspeculatedstrategyinthisﬁeldbecausetargeting
via galactosylated carriers exploit highly speciﬁc interactions of
galactose ligands with endogenous lectin receptors such as
asialoglycoprotein receptor (ASGPR), which is speciﬁcally and
abundantly present on hepatocytes (Jain et al., 2012; Rensen et al.,
2001; Wu et al., 2004). This receptor has been used to deliver to
hepatocytes all kinds of therapeutic compounds ranging from
therapeutic proteins, antiviral agents (Di Stefano et al., 1997) to
anticancer drugs (Di Stefano et al., 2006; Fiume et al., 2005). Active
targeting by coupling galactose (GAL) residues or lactose moieties to
proteins and polymers or by their introduction on the colloidal
surface of nanoparticles or polymeric micelles, allow enhancing the
uptake of drug-loaded systems into hepatocytes with high degree of
selectivity (Fiume and Di Stefano, 2010; Li et al., 2010; Poelstra et al.,
2012; Suo et al., 2010; Suriano et al., 2010; Wu et al., 2010; Yang et al.,
2011; Zheng et al., 2011). In well-differentiated forms of hepatocel-
lular carcinoma (HCC), hepatocytes over-express on the surface the
ASGP-R (Hyodo et al., 1993) and many drug delivery systems have
been already developed to deliver drugs to this receptor using
lactosaminated or galactosaminated substituted drug carriers,
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albumins (Fiume and Di Stefano, 2010).
Sorafenib (Nexavar1) is the ﬁrst drug currently approved by the
USFoodand DrugAdministration(FDA) forthe ﬁrst-line treatmentof
unresectable HCC (Kane et al., 2009; Keating and Santoro, 2009;
Llovet et al., 2008; URL: http://www.cancer.gov/cancertopics/
druginfo/fda-sorafenib-tosylate). It is the ﬁrst systemic therapy to
prolong median survival and the time progression by nearly
3 months in HCC patients, representing the new reference standard
for systemic treatment in HCC patients. The recommended dosage is
400 mg twice daily, but dose reduction or temporary interruption of
sorafenib therapy may be needed to manage adverse events, such as
dermatological hand-foot skin reactions and diarrhoea, that may
signiﬁcantly affect patients quality of life (Chaparro et al., 2008;
Keating and Santoro, 2009; Llovet et al., 2008).
In this paper, we described the construction of polymeric
micelles bearing GAL moieties on the surface. Moreover, their
capability to carry efﬁciently Sorafenib to the liver is demonstrated
by in vivo experiments. Starting polymer was the a,b-poly(N-2-
hydroxyethyl)-D,L-aspartamide (PHEA) (Craparo et al., 2010;
Giammona et al., 1987) to which a proper amount of ethylenedi-
amine (EDA) chains was linked to obtain PHEA-EDA copolymer
(Licciardi et al., 2006) in order to increase reactivity towards
further successive functionalization. Poly-lactic acid (PLA) mole-
cules were subsequently grafted in order to obtain an amphiphilic
copolymer (PHEA-EDA-PLA) (Craparo et al., 2008) able to give self-
assembling polymeric micelles. This derivative subsequently
reacted with lactose, to obtain the PHEA-EDA-PLA-GAL copolymer.
Polymeric micelles were successfully obtained in aqueous media
starting from PHEA-EDA-PLA-GAL copolymer. Physical–chemical
and biological studies were performed on polymeric micelles
obtained from this copolymer in order to demonstrate their
colloidal size, biocompatibility, and their capability to act as
controlled and liver-targeted drug delivery systems.
2. Materials and methods
2.1. Chemicals
SEC poly(ethylene oxide) standards, anhydrous N,N-dimethylfor-
mamide (DMFa), anhydrous dimethylsulfoxide (DMSOa), methanol,
DMSO-d6 (isotopic purity 99.9%), N-hydroxysuccinimide (NHS),
diethylamine (DEA), acetone, diethyl ether, sodium cyanoborohy-
dride, a-lactose, anthrone, were purchased from Sigma–Aldrich
(Italy) and were used as received. Sorafenib was purchased at L.C.
Laboratories (USA); Nexavar was a gift of a HCC patient. RESOMER R
202 (D,L-Polylactic acid, PLA 8000 Da) from Bidachem-Boehringher
Ingelheim (Italy) was also used. SpectraPor dialysis tubing was
purchased from Spectrum Laboratories, Inc. (Italy).
Weight-average molecular weight ðMwÞ of each copolymer was
determined by size exclusion chromatography (SEC) analysis. SEC
system (Waters, Mildford, MA) was equipped with a pump system,
two Phenogel columns from Phenomenex (5 mm particle size,
103 Å and 104 Å of pores size), and a 410 differential refractometer
(DRI) as concentration detector. Analyses was performed with tris
buffer solution 0.1 M at pH 8 as eluent at 37 C with a ﬂux of 0.8 mL/
min and poly(ethylene oxide) standards (range 145–1.5 kDa) to
obtain the calibration curve.
The 1H NMR spectra were recorded by using a Bruker Avance II
300 spectrometer operating at 300 MHz. Centrifugation was
performed using a Centra MP4R IEC centrifuge.
a,b-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA) was pre-
pared via polysuccinimide (PSI) by polycondensation of D,L-
aspartic acid in the presence of H3PO4 at 180 C, followed by
reaction with ethanolamine in DMF solution, and puriﬁed
according to a procedure elsewhere reported (Giammona et al.,1987). Spectroscopic data were in agreement with the attributed
structure. 1H NMR (300 MHz, D2O, 25 C, TMS): d = 2.78 (m, 2H,
CHCH2CONH), d = 3.32 (m, 2H, NHCH2CH2OH), d = 3.63 (m, 2
H, NHCH2CH2OH), d = 4.68 (m, 1H, NHCH(CO)CH2. Weight
average molecular weight of PHEA was 40.3 kDa (Mw/Mn = 1.58),
determined by SEC analysis.
The synthesis of a,b-poly(N-2-hydroxyethyl)(2-aminoethyl-
carbamate)-D,L-aspartamide (PHEA-EDA) copolymer was per-
formed according to the procedure previously published and
spectroscopic data were in agreement with the attributed
structure (Craparo et al., 2013a; Licciardi et al., 2006).
1H NMR (300 MHz, D2O, 25 C, TMS): d = 2.60 (m, 2H,
CHCH2CONH), d = 2.84 (m, 2H, NHCH2CH2NH2), d = 3.16
(m, 2H, NHCH2CH2OH), d = 3.27 (m, 2H, NHCH2CH2NH2),
d = 3.47 (m, 2H, NHCH2CH2OH), d = 3.93 (m, 2H, NHCH2CH2O
(CO)NHCH2CH2NH2), d = 4.52 (m, 1H, NHCH(CO)CH2). The
derivatization degree in EDA (DDEDA), calculated according to the
method reported, was 30.0  0.5 mol%. Mwof PHEA-EDA was
23.3 kDa Mw=Mn ¼ 1:66
 
.
The derivatization of PHEA-EDA with D,L-polylactic acid (PLA) to
obtain the copolymer PHEA-EDA-PLA copolymer was performed
according to a procedure previously published and spectroscopic
data were in agreement with the attributed structure (Craparo
et al., 2008). The derivatization degree in PLA (DDPLA) was
calculated according to the method reported, resulted to be
0.73  0.12 mol%. Mw of PHEA-EDA-PLA, determined by SEC
analysis, was found to be 19.3 kDa Mw=Mn ¼ 1:60
 
.
2.2. PHEA-EDA-PLA-GAL synthesis
Galactosylated PHEA-EDA-PLA copolymer (PHEA-EDA-PLA-
GAL) was synthesized by a reductive amination of lactose with
primary amine functions of PHEA-EDA-PLA in the presence of
sodium cyanoborohydride, according to the procedure previously
published and spectroscopic data were in agreement with the
attributed structure (Craparo et al., 2013a).
1H NMR (300 MHz, D2O, 25 C, TMS): d = 0.79 and d = 1.24 (2d,
3HPLA, OCOCH(CH3)O), d = 2.75 (m, 2HPHEA, CHCH2CONH),
d = 2.99 (m, 2HEDA, NHCH2CH2NH2), d = 3.28 (m, 2HPHEA,
NHCH2CH2OH), d = 3.40 (m, 2HEDA, NHCH2CH2NH2), d = 3.58
(m, 2HPHEA, NHCH2CH2OH), d = 3.62–3.77 (m, 12 Hsugar, CH2OH
and CH(OH) sugar protons), d = 4.06 (m, 2HPHEA,
NHCH2CH2O(CO)NHCH2CH2NH2), d = 4.41 (s, 1 HGAL, anomeric
proton), d = 4.64 (m, 1HPHEA, NHCH(CO)CH2).
The Mw was found to be 24.3 kDa Mw=Mn ¼ 1:66
 
.
The amount of GAL grafted onto PHEA-EDA-PLA-GAL copolymer
measured by using anthrone-sulphuric acid colorimetric method
was 0.86 wt% (corresponding to 1.22 mol%) (Craparo et al., 2013a;
Song et al., 2009).
The critical aggregation concentration (CAC) of PHEA-EDA-PLA-
GAL copolymer, determined by collecting steady-state ﬂuores-
cence spectra of pyrene probe in the presence of increasing
concentrations of that copolymer, resulted to be 4.1 107M
(Craparo et al., 2013a).
2.3. Preparation of sorafenib-loaded PHEA-EDA-PLA-GAL
and PHEA-EDA-PLA micelles
To obtain sorafenib-loaded micelles, the evaporation method
was chosen according to the published procedure (Craparo et al.,
2009; Craparo et al., 2011; Ngawhirunpat et al., 2009). In particular,
these micelles were prepared by closely mixing an appropriate
amount of PHEA-EDA-PLA-GAL or PHEA-EDA-PLA and sorafenib to
obtain a ﬁnal copolymers/drug weight ratio equal to 10:1. Then,
aliquots of ethanol (total volume = 1.5 mL) were added and, after
evaporation of the solvent at room temperature under a gentle
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25 mL of volume. The obtained dispersions were submitted to
ultrasounds for 10 min, centrifuged at 4000 rpm, at 25 C for
10 min, ﬁltered and lyophilised.
2.4. Drug loading determination
The amount of sorafenib blended into PHEA-EDA-PLA-GAL and
PHEA-EDA-PLA micelles (drug loading, DL%), was determined by the
HPLC method. The column was a Gemini C18 (mBondpack, 5 mm,
250  46 mm i.d., obtained from Waters); the mobile phase was a
mixture of methanol:K2HPO4 (0.1 M, pH 8.7) 90:10 v/v with a ﬂow
rate of 0.7 mL/min, the column temperature was 25 C, and the
detection wavelength was 264 nm. 40 mL sample was injected into
the column. The obtained peak area (tr = 5.68 min) corresponding to
sorafenib amount blended into PHEA-EDA-PLA-GAL or PHEA-EDA-
PLA micelles was compared with a calibration curve obtained by
plotting areas versus standard solution concentrations of sorafenib
in methanol in the range of 40–0.1 mg/mL (y = 4E + 08x, R2 = 0.996).
Results were expressed as the weight percent ratio between the
loaded sorafenib and the dried system (micelles + sorafenib).
2.5. Dimensional analysis
The mean diameter and width distribution of each sample were
determined by Photon Correlation Spectroscopy (PCS) by using a
Zetasizer Nano ZS (Malvern Instrument, Malvern, UK) that utilizes
the Non-Invasive Back-Scattering (NIBS) technique. The measure-
ments were carried out at a ﬁxed angle of 173 and at 25 C on each
dispersion obtained by using NaCl 0.9 wt% and phosphate buffered
saline (PBS) aqueous solutions at pH 7.4 as suspending media
ﬁltered on nylon 5 mm.
Each dispersion was kept in a cuvette and analyzed in triplicate.
The deconvolution of the measured correlation curve to an
intensity size distribution was accomplished by using a non-
negative least squares algorithm.
2.6. Zeta potential measurements
The zeta potential values were measured using principles of
laser doppler velocitometry and phase analysis light scattering
(M3-PALS technique) by using Zetasizer Nano ZS Malvern
Instrument. Samples were dispersed in ﬁltered NaCl 0.9 wt% and
PBS at pH 7.4 aqueous solutions, ﬁltered on nylon 5 mm and
analysed in triplicate.
2.7. Transmission electron microscopy (TEM) analysis
TEM micrographs were acquired by using a JEM-2100 (JEOL,
Japan) electron microscope, operating at a 200 kV accelerating
voltage. A few tens of a milligram of the freeze-dried samples were
dispersed in 2 mL of bi-distilled water and a small drop of the
dispersion was deposited on a 300 mesh carbon-coated copper
grid, which was introduced into the TEM analysis chamber after
complete solvent evaporation.
2.8. Drug release studies
The stability of PHEA-EDA-PLA and PHEA-EDA-PLA-GAL
micelles was studied at pH 1.6, 6.5 and 7.4 in sink conditions by
evaluating the release of sorafenib by a dialysis method.
To evaluate gastric stability, a ﬂuid simulating conditions in the
stomach in the fasted state (FaSSGF) was used by preparing a
solution of NaCl (30 mM), pepsin (0.1 mg/ml), sodium taurocholate
(80 mM) and lecithin (20 mM), at pH 1.6 by addition of HCl
(Vertzoni et al., 2005).To evaluate intestinal stability, a ﬂuid simulating the proximal
small intestine conditions in fasted state (FaSSIF) was used by
preparing a solution of monobasic potassium phosphate (3.9 g/l),
KCl (7.7 g/l), sodium taurocholate (3 mM) and lecithin (0.75 mM), at
pH 6.5 by addition of NaOH (Galia et al., 1998).
To evaluate plasma and interstitial stability, phosphate buffered
saline (PBS, NaCl, Na2HPO4, KH2PO4) at pH 7.4 containing 50% fetal
bovine serum (FBS) was used (Zhang et al., 2011).
Each sample (total drug amount = 0.48 mg) was dispersed in
aliquots of the proper medium (2 mL), placed in a dialysis bag
(MWCO 12–14 kDa) immersed in 48 mL of the same medium, and
then incubated in a thermostatic shaker (100 rpm, 37 C). At
scheduled time-points, aliquots of the receiver medium (0.5 mL)
was taken and replaced by fresh medium (0.5 mL). The sorafenib
amounts in each sample, after adding methanol (1 mL) to
precipitate proteins and extract the drug, were determined by
the HPLC method mentioned above (to calculate the cumulative
Sorafenib release percentages).
A control experiment to determine the release behavior of the
free drug was also performed: an appropriate amount of sorafenib
was dispersed in the proper medium, in order to have a sorafenib
ﬁnal concentration equal to which of micelles, put into a dialysis
tube (MWCO 12–14 kDa) and immersed into the proper medium.
The amount of sorafenib was detected as reported above.
2.9. Haemolytic test
Human erythrocytes isolated from fresh citrated-treated blood
were collected by centrifugation at 2200 rpm for 10 min at 4 C. The
pellet was washed four times with PBS at pH 7.4 by centrifugation
and suspended in the same buffer. Afterwards, it was diluted in PBS
at pH 7.4 to a ﬁnal concentration of 4% erythrocytes. This stock
dispersion was always freshly prepared and used within 24 h after
preparation. Sorafenib, empty or sorafenib-loaded PHEA-EDA-PLA
and PHEA-EDA-PLA-GAL micelle dispersions (with a drug concen-
tration ranging between 0.1–0.5 mg/ml) were added to the
erythrocyte suspension and incubated for 2 h at 37 C under
constant shaking. After centrifugation, the release of haemoglobin
was determined by photometric analysis of the supernatant at
540 nm. Complete haemolysis was achieved by using a 1 wt%
aqueous solution of Triton X-100 (100% control value). Each
experiment was performed in triplicate and repeated twice. The
erythrocyte lysis percentage was calculated according to the
following formula:
% lysis ¼ Asample  Ablank
 
A100% lysis  Ablank
  ¼ 100
where Asample is the absorbance value of the haemoglobin released
from erythrocytes treated with sorafenib, empty or sorafenib-
loaded micelle dispersion; Ablankis the absorbance value of the
haemoglobin released from erythrocytes treated with PBS buffer,
and A100% lysis is the absorbance value of the haemoglobin released
from erythrocytes treated with 1% Triton X-100 solution.
2.10. Animals
Experiments were performed using adult female mice (C57BL/
6SnJ) weighting 20–25 g obtained from Harlan Laboratories (San
Pietro al Natisone, Udine, Italy). Animals were kept under
environmentally controlled condition, ambient temperature
24 C, humidity 40% and 12 h light/dark cycle with food and water
ad libitum. Procedures involving animals and their care were
conducted in conformity with institutional guidelines which are in
compliance with national (D.L. n. 116, G.U., suppl. 40, 18 Feb. 1992)
and international laws and policies (NIH Guide for the Care and Use
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Council Directive 86/609, OJ L 358,1,1 December 12, 1987; Giles,
1987).
2.11. Experimental protocol
Mice received by gavage a single oral dose of 5.7 mg/kg of drug
(as sorafenib tosylate, or sorafenib-loaded micelles), after disper-
sion in isotonic normal saline solution. The dose selected was an
approximate equivalent conversion from the recommended daily
dose for adults with refractory cancers. Control mice received an
equal volume of isotonic normal saline solution.
Animals were then sacriﬁced at different time-points (1, 2, 4 h)
following drug administration. Blood was taken by cardiac
puncture, and the following organs were collected: lungs, spleen,
liver and kidneys. Specimens were then weighted and stored at
80 C until drug analyses were performed.
To extract and quantify the amount of drug, each organ or blood
sample was mixed with Tris buffer (2 mL, 1 M, pH 8) in a 15 ml glass
tube, and homogenized using a Ultraturrax for 15 min (not for
blood). Then, methanol (1 mL) was added to precipitate proteins.
Samples were extracted three time with diethyl ether (2 mL),
followed by centrifugation at 4000 rpm (5 min). After every solvent
addition, the centrifuge tubes were shaken for 20 min at room
temperature, and centrifuged for 5 min at 4000 rpm. The organic
layers were transferred into a glass tube and evaporated to dryness
at 35 C under a gentle stream of nitrogen. The dried residue was
reconstituted in methanol (0.6 mL) and a 40 mL volume was
injected into the HPLC system in conditions described above.
The extraction efﬁciency in each organ or blood was previously
determined by spiking known amounts of sorafenib in blood or
homogenate organs obtained from un-administered animals and
by analysing each mixture as described above.
2.12. Statistical analysis
The statistical analysis of the samples was performed by using a
Student’s t-test. A p-value < 0.05 was considered to be indicative of
statistical signiﬁcance while a p-value < 0.01 was considered as
highly signiﬁcant. All data were reported as mean  SD, unless
otherwise stated.
3. Results and discussion
a,b-poly(N-2-hydroxyethyl)(2-aminoethylcarbamate)-D,L-
aspartamide (PHEA-EDA) copolymer is an appropriate starting
macromolecule to design novel amphiphilic copolymers for
biomedical application (Craparo et al., 2008; Craparo et al.,
2013a; Licciardi et al., 2006).
In order to develop new colloidal liver-targeted polymeric
carriers for sorafenib, a PHEA-EDA amphiphilic derivative able
to self-assemble in aqueous media was prepared (Craparo et al.,
2013a). In particular, poly-lactic acid (PLA) and lactose were
chemically grafted onto the amine groups of PHEA-EDA to
obtain the PHEA-EDA-PLA-GAL graft copolymer. In this way,
the grafting of each PLA residue permits to introduce a
hydrophobic biodegradable tail that contributes to obtain
stable micelles. The subsequent grafting of GAL moieties onto
the PHEA-EDA-PLA backbone permits to obtain a sugar-targeted
polymeric conjugate for a speciﬁc therapy of liver diseases, due
to the presence of carbohydrate receptors in the liver, i.e., the
asialoglycoprotein receptors (ASGPR) in hepatocytes (Craparo
et al., 2013b; Fiume and Di Stefano, 2010; Li et al., 2010;
Medina et al., 2011).3.1. Synthesis and characterization of PHEA-EDA-PLA-GAL graft
copolymer
The derivatization reaction of PHEA-EDA with PLA was carried
out in organic solvent using the NHS derivative of PLA (PLA-NHS),
in the presence of diethylamine (DEA), as described previously
(Craparo et al., 2008; Craparo et al., 2013a). The derivatization
degree in PLA residues (DDPLA) for PHEA-EDA-PLA graft copolymer
was expressed as mean value of eight determinations and resulted
to be 0.73  0.12 mol, indicating that about one PLA tail is inserted
on the PHEA-EDA backbone every one hundred repeating units.
The weight-average molecular weight Mw
 
and the polydispersity
index Mw=Mn
 
values of PHEA-EDA-PLA graft copolymer,
obtained in aqueous environment by SEC analysis, were found
to be equal to 19.3 kDa and 1.60, respectively.
In order to develop a hepatocyte-targeted carrier, GAL residues
were introduced in the PHEA-EDA-PLA side chains by leaving to
react it with lactose moieties (Craparo et al., 2013a).
This derivatization reaction was carried out by a single
synthetic step in organic solvent involving the reductive amination
of lactose with PHEA-EDA-PLA primary amine functions, in the
presence of sodium cyanoborohydride for 4 h at 40 C (Craparo
et al., 2013a). The chemical structure of PHEA-EDA-PLA-GAL graft
copolymer is depicted in Fig. 1.
The amount of GAL grafted onto PHEA-EDA-PLA-GAL copolymer
measured by using anthrone–sulphuric acid colorimetric method
was 0.86 wt% (corresponding to 1.22 mol%) (Craparo et al., 2013a;
Song et al., 2009). The Mw
 
and the Mw=Mn
 
values of PHEA-
EDA-PLA-GAL graft copolymer, obtained in aqueous environment,
were found to be equal to 24.3 kDa and 1.66, respectively.
The critical aggregation concentration (CAC) of PHEA-EDA-PLA-
GAL copolymer, determined by collecting steady-state ﬂuores-
cence spectra of pyrene probe in the presence of increasing
concentrations of that copolymer resulted to be 4.1 107M, while
PHEA-EDA-PLA copolymer showed a CAC equal to 2.6  106M in
the same experimental conditions (Craparo et al., 2013a).
3.2. Preparation and characterization of empty and sorafenib-loaded
micelles
To obtain colloidal nanostructures in aqueous media starting
from obtained PHEA-EDA-PLA-GAL copolymer, the evaporation
method was chosen according with the published procedure
(Craparo et al., 2009; Craparo et al., 2011; Craparo et al., 2013a;
Ngawhirunpat et al., 2009).
PHEA-EDA-PLA-based micelles were prepared following the
same procedure in order to obtain nontargeted systems to use for
comparison with targeted ones in further experiments. Brieﬂy,
this technique involved the simple dispersing of each dry
copolymer (in the presence of the drug, to obtain drug-loaded
systems) by adding aliquots of ethanol, then its evaporation at
room temperature under a gentle stream of nitrogen to form a
copolymer/prodrug ﬁlm. This latter was then dispersed in bi-
distilled water and the amount of drug exceeded the solubilisa-
tion capacity of micelles was removed by centrifugation and
ﬁltration. Obtained aqueous dispersions were lyophilised to
recover drug-loaded micelles.
The drug loading (DL%), determined by HPLC and expressed as
the weight percent ratio between the loaded sorafenib and the
dried system, resulted to be 3.0 and 3.6 wt%, respectively, for PHEA-
EDA-PLA-GAL or PHEA-EDA-PLA micelles.
Empty and sorafenib-loaded PHEA-EDA-PLA-GAL or PHEA-
EDA-PLA micelles, after re-dispersion in a proper medium, were
characterised in terms of mean size and width of distribution
values by using photon correlation spectroscopy (PCS). Analytical
data are reported in Table 1.
Table 1
Mean size, width of distribution and z potential values in PBS and NaCl 0.9 wt% of
empty and sorafenib-loaded PHEA-EDA-PLA and PHEA-EDA-PLA-GAL micelles.
Sample Dispersing
medium
Mean size
(nm)(S.D.)
z potential
(mV)(S.D.)
PHEA-EDA-PLA micelles PBS 21.6  3.2 2.2  3.5
NaCl 0.9% 29.5  7.2 1.2  2.8
PHEA-EDA-PLA-GAL micelles PBS 21.5  6.8 1.7  3.0
NaCl 0.9% 28.2  7.9 3.9  1.9
Sorafenib-loaded
PHEA-EDA-PLA micelles
PBS 120.2  76.8 +5.1  2.7
NaCl 0.9% 147.4  40.8 +3.3  2.6
Sorafenib-loaded
PHEA-EDA-PLA-GAL micelles
PBS 125.7  53.7 +4.3  3.2
NaCl 0.9% 101.8  64.3 +1.9  2.1
Fig. 1. Chemical structure of PHEA-EDA-PLA-GAL graft copolymer (n = 111).
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structures showed a size distribution with an average diameter of
about 30 nm in NaCl 0.9%, with non-signiﬁcant differences in
diameters when these were measured in PBS aqueous solution.
When sorafenib was entrapped into PHEA-EDA-PLA and PHEA-
EDA-PLA-GAL micelles (during the micelle formation), the mean
size of both nanostructures was strongly affected. In particular,
drug-loaded PHEA-EDA-PLA nanostructures showed a sizeFig. 2. Representative TEM images of PHEA-EDA-PLA-GAL micelles, empty (a, 80,000) 
100 nm in image (b).distribution with an average diameter of 147.41 nm in NaCl
0.9%, while drug-loaded PHEA-EDA-PLA-GAL nanostructures
showed an average diameter of 101.82 nm in the same medium.
Therefore, the drug entrapment increased the mean size of either
PHEA-EDA-PLA or PHEA-EDA-PLA-GAL micelles presumably for a
size increase of the hydrophobic core due to the drug presence.
Moreover, also for drug-loaded systems, in PBS aqueous solution,
mean size values showed small differences compared to those
obtained in NaCl 0.9%.
Thez potentialvalues of these structures,also reported inTable 1,
were slightly negative for empty PHEA-EDA-PLA and PHEA-EDA-
PLA-GAL systems and changed to slightly positive for drug-loaded
systems in either NaCl 0.9% or in PBS aqueous solution.
In order to conﬁrm the nanometric size and to investigate the
morphology of empty or sorafenib-loaded PHEA-EDA-PLA-GAL
micelles, TEM was used and representative TEM images of PHEA-
EDA-PLA-GAL micelles, empty and loaded with sorafenib have
been reported in Fig. 2.
These images were consistent with ﬁndings obtained from
dimensional analysis, greater drug-loaded mean size than that of
empty micelles, and also revealed a spherical shape of investigated
samples.and loaded with sorafenib (b, 30,000). The bars represent: 50 nm in image (a) and
Fig. 3. Sorafenib diffusion proﬁle across the dialysis membrane and release proﬁles
of sorafenib from PHEA-EDA-PLA and PHEA-EDA-PLA-GAL micelles in: (a) FaSSGF
(pH 1.6) for 4 h; (b) FaSSIF (pH 6.5) and in PBS (pH 7.4)/FCS mixture for 24 h. Data
represent mean  S.D., (n = 3).
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The micelle stability after administration, before they reach the
target site to release the entrapped drug, is a need to obtain
optimization of bioavailability and reduction of side effects.
In order to evaluate the potential stability of obtained micelles,
a drug release study was carried out in physiological – mimicking
ﬂuids in sink conditions to assess their capability to retain the
encapsulated drug under sink conditions and/or to release it slowly
in physiological media. In particular, these studies were carried out
in fasted state simulated gastric ﬂuid (FaSSGF) at pH 1.6 for 4 h to
mimic gastric conditions, in fasted state simulated intestinal ﬂuid
(FaSSIF) at pH 6.5 for 24 h to mimic intestinal conditions, and in
phosphate buffer solution (PBS) at pH 7.4/foetal calf serum (FCS)
(50:50) for 24 h to mimic extracellular and plasmatic conditions
(Francis et al., 2005; Roger et al., 2010; Zhang et al., 2011).
The micelle stability was deduced by evaluating the amount of
released drug from micelles at preﬁxed time intervals across a
dialysis tube. Moreover, the sorafenib diffusion proﬁle alone was
investigated in each medium in order to determine the diffusion
rate of the free drug across the dialysis membrane. The amount of
released sorafenib was expressed as percentage ratio between the
weight of released drug at the preﬁxed time and the total amount
of sorafenib loaded into micelles.
Fig. 3a and b show the drug dissolution and release proﬁles of
sorafenib from PHEA-EDA-PLA and PHEA-EDA-PLA-GAL micelles in
FaSSGF, and in FaSSIF and PBS, respectively.
As shown in Fig. 3a, after 4 h incubation in FaSSGF, the
cumulative release of sorafenib was about 4% from both PHEA-
EDA-PLA and PHEA-EDA-PLA-GAL micelles. As show in Fig. 3b,
after 24 h incubation, the cumulative release of sorafenib was
about 6.6% and 4.2% in FaSSIF, and 12.9% and 11.6% in PBS from
PHEA-EDA-PLA and PHEA-EDA-PLA-GAL micelles, respectively.
These results reveal that micelles were adequately stable in all
the investigated media at all the incubation period. Moreover, the
burst release was not observed from both micelles in all incubation
conditions, very remarkable observation since fast release of drug
may result in fast elimination of drug in vivo, leading to a lower
antitumor efﬁcacy.
3.4. In vitro biological characterization
Hemocompatibility is an essential requirement for a successful
use of PHEA-EDA-PLA-GAL micelles as carriers for targeted sorafenib
delivery into hepatic cells, not only after intravenous administration
but also after oral administration, being the bloodstream the main
path for these systems to reach and target the liver after
gastrointestinal absorption. Therefore, the potential sorafenib-
containing micelle interaction with erythrocyte membranes and
their hemolytic effects were investigated by hemolysis experiments,
incubating under proper conditions empty or sorafenib-loaded
PHEA-EDA-PLA-GAL or PHEA-EDA-PLA micelles, together with
erythrocytes and quantifying the haemoglobin release.
Erythrocytes were treated with 1 wt% Triton X-100 and PBS at
pH 7.4 in order to obtain the values corresponding to 100% and 0%
of lysis, respectively. Erythrocytes were incubated with aqueous
dispersions of empty or sorafenib-loaded nanoparticles (at micelle
concentrations of 1.6, 3.3 and 6.6 mg/ml) for 1 h at 37 C. Under
these conditions, empty or prodrug-loaded micelles showed no
signiﬁcant haemolytic effects, indicating no detectable interaction
with red blood cell membranes. In fact, the percentage of
haemolysis at the highest copolymer concentration was always
less than 6.0%. In particular, haemolysis effect at the highest
copolymer concentration resulted to be equal to 2.6 and 5.9% for
empty and drug-loaded PHEA-EDA-PLA micelles, respectively; to
1.3 and 3.4% for empty and drug-loaded PHEA-EDA-PLA-GALmicelles, respectively. Moreover, no erythrocyte aggregation, after
incubation with empty or prodrug-loaded micelles, was detected
by microscopic observations (data not shown).
These results demonstrate that micelles do not cause lysis of red
blood cell membranes under chosen experimental conditions. The
absence of cellular toxicity of empty micelles was already
demonstrated (Craparo et al., 2013a).
3.5. In vivo experiments
To evaluate whether the entrapment of sorafenib into PHEA-
EDA-PLA-GAL micelles could increase the drug bioavailability and
178 E.F. Craparo et al. / International Journal of Pharmaceutics 466 (2014) 172–180targeting to the liver, in vivo biodistribution studies were carried
out. Oral administration route was chosen to carry out these
experiments, since it is the best route in terms of patient
compliance and currently sorafenib is administer in patients as
Nexavar tablet.
In the ﬁeld of oral drug delivery, drug encapsulation into
polymeric carriers, such as polymeric micelles, could reduce several
drawbacks usually associated with oral administration, whichFig. 4. % of sorafenib amount on total administered dose 1, 2 and 4 h post oral administra
sorafenib-loaded PHEA-EDA-PLA-GAL micelles, in (a) liver, (b) kidneys, (c), spleen, (d) dramatically decrease the bioavailability of the drug. In particular,
encapsulation could protect sensitive drugs from degradation in
stomach and gut lumen, enhance absorption in the intestine by
increasing water solubility, overcome drug resistance mechanisms
(MDR) by altering the absorption pathway from transcellular to
paracellular or transcytosis routes (Gaucher et al., 2010; Roger et al.,
2010). Moreover, the capability of some polymers to increase the
drug adsorption through the gastro-intestinal mucosa either bytion to adult female mice. , Nexavar; , sorafenib-loaded PHEA-EDA-PLA; and ,
lung and (e) blood, (n = 2 animals/time point).
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has been also reported (Benny et al., 2008; Gaucher et al., 2010;
Mathot et al., 2007).
In our experiments, three formulations were used for the
treatment: the powdered commercial tablet (“Nexavar”, contain-
ing sorafenib tosylate) and sorafenib entrapped into both PHEA-
EDA-PLA-GAL and PHEA-EDA-PLA micelles. These formulations
were orally administered by gastric gavage, after dispersion in the
vehicle (isotonic saline solution) at the single dose of 5.7 mg kg1 of
the body weight.
After 1, 2 and 4 h post administration, the concentration of
sorafenib in liver, spleen, lung, kidney and blood was determined
by HPLC analysis, as described in the experimental section. Data
(expressed as drug weight percentage on the total administered
dose) are summarized in Fig. 4a–e, respectively for liver, kidneys,
spleen, lung and blood, as a function of time.
In the liver, 1 h post administration (Fig. 4a), the recovered drug
amounts were very low and no signiﬁcant differences were found
depending on the administered sample. Indeed, 2 h post adminis-
tration, the sorafenib concentration in the liver, when it was
administered into targeted drug-loaded micelles, was signiﬁcantly
higher than when administered into non-targeted drug-loaded
micelles (p < 0.05), or as free drug (sorafenib tosylate) (p < 0.02). In
particular, when the sorafenib-loaded PHEA-EDA-PLA-GAL and
PHEA-EDA-PLA micelles were administered, the amounts of drug
found into the liver were equal respectively to 35 and 19.8 wt% on
total administered dose, while when sorafenib was administered
as Nexavar, the amount of drug found into the liver was equal to
2.7 wt% on total administered dose.
4 h post administration, the amounts of sorafenib in the liver
were signiﬁcantly decreased compared to those found after 2 h
administration; but in the case of the targeted sample (drug-
loaded galactosylated micelles), the amount was signiﬁcantly
higher than those found when Nexavar or drug-loaded non
galactosylated micelles were administered (p < 0.02). In particular,
when the sorafenib-loaded PHEA-EDA-PLA-GAL micelles were
administered, the amount of drug found into the liver was equal to
19.9 wt% on total administered dose, while when sorafenib was
administered as Nexavar or loaded into PHEA-EDA-PLA micelles
the amounts of drug found into the liver were equal to 2.8 and 4.5%
p/p on total administered dose, respectively. This result means that
administered sorafenib entrapped into targeted micelles reached
the target organ, the liver, to a much higher extent than the drug
administered as free or loaded into non-targeted micelles, and it
accumulated in the same organ.
As reported in Fig. 4b an accumulation into kidneys after 2 h
post administration was appreciated when the administered drug
is loaded into micelles compared to Nexavar. However, in the case
of galactosylated micelles the drug percentage is halved compared
to non-galactosylated micelles. Moreover the disappearance of the
drug in kidneys 4 h post administration is in agreement with the
hypothesis that the drug, as administered as micelles, is following
the normal elimination pattern by kidney.
In Fig. 4b–e, the drug amounts found into kidneys, spleen, lung
and blood are also reported as function of administration time.
Although some signiﬁcant differences in recovered drug amounts
were almost evidenced in these organs, the signiﬁcantly increased
liver accumulation obtained with targeted micelles could allow to
a reduction of administered dose.
From these graphics, the total amount of recovered drug 1, 2 and
4 h post administration in investigated organs and blood for each
sample was calculated, and it resulted to be respectively 5.5, 53.6 and
22.2 wt% on total administered dose for galactosylated micelles, 4.7,
52.6 and 6.4 wt% for non-galactosylated micelles and 5.5, 8.2 and
3.5 wt%forNexavar. Thisfactcouldbeexplainedconsideringboththe
increased effect on bioavailability due to entrapment into polymericcolloidal carriers and also their potential absorption towards the
gastro-intestinal mucosa (Benny et al., 2008; Gaucher et al., 2010;
Mathot et al., 2007; Roger et al., 2010).
Therefore, all together these results seem to demonstrate that
the use of galactosylated PHEA-EDA-PLA-GAL micelles increased
the total absorbed drug and the liver targeting of sorafenib, and
that this could be due to the contributor of the ASGR to
internalization.
4. Conclusions
In this paper, we describe the synthesis and the characterization
of a novel galactosylated graft amphiphilic copolymer, PHEA-EDA-
PLA-GAL, able to self-assemble and form hepatocytes-targeted
micelles carrying sorafenib. Empty and drug-loaded micelles were
obtained and characterised in terms of zeta potential, that results
positive, and colloidal mean size, showing values in the order of
few ten nanometres. These sizes were conﬁrmed by TEM analysis
that showed also spherical shape of investigated samples. The DL%
of prodrug loaded-galactosylated micelles resulted to be 3.0 wt%.
Preliminary in vitro studies demonstrated that these carriers
have no haemolytic activity.
Biodistribution studies demonstrated that the amount of
sorafenib entrapped into the galactosylated systems reaching
the liver was signiﬁcantly greater than both free sorafenib and
sorafenib-loaded into non-targeted micelles, and it is more evident
at longer times. Therefore, the presence of GAL on PHEA-EDA-PLA-
GAL micelles confers them the capability to give an enhanced
accumulation of sorafenib into the liver compared with that
obtained by non-galactosylated systems, demonstrating the
potential contribution of ASGPR to the internalization process.
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